NVP-ADW742 b
CAS No. 475488-23-4
NVP-ADW742 b( ADW | GSK 552602A | ADW742 )
Catalog No. M19445 CAS No. 475488-23-4
NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM >16-fold more potent against IGF-1R than InsR; little activity to HER2 PDGFR VEGFR-2 Bcr-Abl and c-Kit.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 61 | In Stock |
|
| 5MG | 96 | In Stock |
|
| 10MG | 160 | In Stock |
|
| 25MG | 289 | In Stock |
|
| 50MG | 532 | In Stock |
|
| 100MG | 759 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNVP-ADW742 b
-
NoteResearch use only, not for human use.
-
Brief DescriptionNVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM >16-fold more potent against IGF-1R than InsR; little activity to HER2 PDGFR VEGFR-2 Bcr-Abl and c-Kit.
-
DescriptionNVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM >16-fold more potent against IGF-1R than InsR; little activity to HER2 PDGFR VEGFR-2 Bcr-Abl and c-Kit.
-
In VitroNVP-ADW742 (ADW742; 0.1-10 μM; 72 hours) dose-dependently inhibits serum-induced cell growth in all cell lines. NVP-ADW742 (0.1-9 μM; 20 min) blocks IGF-1-induced phosphorylation of IGF-1R and its known downstream target Akt at submicromolar concentrations. NVP-ADW742 has much higher IC50 values for other kinases (IC50>10 μM for HER2, PDGFR, VEGFR-2, or Bcr-Abl p210; and IC50>5 μM for c-Kit). Cell Viability Assay Cell Line:A panel of cell lines from multiple myeloma (MM), other hematologic malignancies and solid tumors Concentration:0.1, 0.5, 1, 2, 5, 10 μM Incubation Time:72 hours Result:Dose-dependently inhibited serum-induced cell growth in all cell lines.Western Blot Analysis Cell Line:NWT-21 cells Concentration:0.1, 0.3, 1, 3, 9 μM Incubation Time:20 min Result:Blocked IGF-1-induced phosphorylation of IGF-1R and its known downstream target Akt at submicromolar concentrations.
-
In VivoNVP-ADW742 (ADW742; 10 mg/kg for IP or 50 mg/kg for orally; twice daily for 19 days) significantly suppresses tumor growth and prolongs the survival of mice. Animal Model:6- to 8-week-old male SCID/NOD mice with diffuse skeletal lesions of luciferase-expressing MM cells Dosage:10 mg/kg (IP) or 50 mg/kg (orally) Administration:IP or orally; twice daily for 19 days Result:Significantly suppressed tumor growth and prolonged the survival of mice.
-
SynonymsADW | GSK 552602A | ADW742
-
PathwayAngiogenesis
-
TargetIGF-1R
-
RecptorIGF-1R
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number475488-23-4
-
Formula Weight453.58
-
Molecular FormulaC28H31N5O
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mg/mL (22.04 mM) warmed;Ethanol:3 mg/mL (6.61 mM);Water:<1 mg/mL
-
SMILESC1CCN(C1)CC2CC(C2)N3C=C(C4=C3N=CN=C4N)C5=CC(=CC=C5)OCC6=CC=CC=C6
-
Chemical Name5-(3-(benzyloxy)phenyl)-7-((1r3r)-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[23-d]pyrimidin-4-amine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
LMPTP INHIBITOR 1 hy...
LMPTP INHIBITOR 1 is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an IC50 of 0.8 μM LMPTP-A.
-
IGF-I 24-41
IGF-I (24-41) is a 24-41 amino acid fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).
-
Ganitumab
Ganitumab (AMG 479) is a highly potent monoclonal antibody targeting the type 1 insulin-like growth factor receptor (IGF1R). Recognized for binding IGF1R at low concentrations with a KD value of 0.22 nM, Ganitumab inhibits IGF1R interactions with IGF1 and IGF2 in mice, making it useful for cancer research.
Cart
sales@molnova.com